Correlation of trastuzumab treatment benefit with quantitative HER2 expression levels in HER2 positive metastatic breast cancer.

被引：0
|
作者：
Bachmeier, Beatrice
Sperinde, Jeff
Weidler, Jodi Marie
Lie, Yolanda
Chenna, Ahmed
Winslow, John
Engel, Jutta
Schubert-Fritschle, Gabriele
Sommerhoff, Christian
Petropoulos, Christos J.
Bates, Michael Patrick
Huang, Weidong
Nerlich, Andreas
机构：
[1] Univ Munich, Inst Lab Med, Munich, Germany
[2] Monogram Biosci, San Francisco, CA USA
[3] Cepheid Inc, Sunnyvale, CA USA
[4] Univ Munich, Inst Med Informat Biostat & Epidemiol, Munich, Germany
[5] Univ Hosp Munich, Inst Med Informat Biometry & Epidemiol IBE, Munich, Germany
[6] Home, Sunnyvale, CA USA
[7] Monogram Biosci Inc, LabCorp, Pleasanton, CA USA
[8] Munich Municipal Hosp, Munich, Germany
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 33卷 / 15期
关键词：
D O I：
10.1200/jco.2015.33.15_suppl.593
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
593
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Application of Tucatinib and Trastuzumab: Dual Anti HER2 Therapy Against HER2 Positive Breast Cancer
    Sumanpreet Kaur
    Rajasri Bhattacharyya
    Dibyajyoti Banerjee
    Jaya Shukla
    Indian Journal of Clinical Biochemistry, 2021, 36 : 124 - 125
  • [22] Application of Tucatinib and Trastuzumab: Dual Anti HER2 Therapy Against HER2 Positive Breast Cancer
    Kaur, Sumanpreet
    Bhattacharyya, Rajasri
    Banerjee, Dibyajyoti
    Shukla, Jaya
    INDIAN JOURNAL OF CLINICAL BIOCHEMISTRY, 2021, 36 (01) : 124 - 125
  • [23] The role of serum HER2 as an alternative to fluorescence in situ hybridization for HER2 in metastatic breast cancer.
    Kong, SY
    Kwon, Y
    Lee, DH
    Lee, JS
    Lee, ES
    Ro, J
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 48S - 48S
  • [24] Issues and controversies in the treatment of HER2 positive metastatic breast cancer
    Amar, Surabhi
    Moreno-Aspitia, Alvaro
    Perez, Edith A.
    BREAST CANCER RESEARCH AND TREATMENT, 2008, 109 (01) : 1 - 7
  • [25] Issues and controversies in the treatment of HER2 positive metastatic breast cancer
    Surabhi Amar
    Alvaro Moreno-Aspitia
    Edith A. Perez
    Breast Cancer Research and Treatment, 2008, 109 : 1 - 7
  • [26] Prospective Validation and Characterization of HER2 Positive Circulating Tumor Cells in Patients with HER2 Negative Metastatic Breast Cancer.
    Olson, E. M.
    Flores, L. M.
    Najita, J. S.
    Curley, C.
    Jeong, J.
    Murray, K.
    Savoie, J. J.
    Winer, E. P.
    Krop, I. E.
    CANCER RESEARCH, 2011, 71
  • [27] HER2Δ16 expression in HER2-positive breast cancer
    De Yao, Jocelyn Torres
    Sun, Danyu
    Galehouse, Donna
    Shorten, Scott
    Haller, Nairmeen
    Rehmus, Esther Hoogland
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [28] HER2Δ16 expression in HER2-positive breast cancer
    De Yao, Jocelyn Torres
    Sun, Danyu
    Galehouse, Donna
    Shorten, Scott
    Haller, Nairmeen Awad
    Rehmus, Esther Hoogland
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (26)
  • [29] Correlation between serum HER2 extracellular domain (HER2 ECD) levels and tumour size in early, advanced and metastatic breast cancer with HER2 overexpression
    Makino, H.
    Tengan, H.
    Tatsuda, K.
    Hashidate, H.
    Mio, K.
    Kiguchi, T.
    Yamazaki, M.
    EUROPEAN JOURNAL OF CANCER, 2014, 50 : S114 - S115
  • [30] HER2 status and benefit from adjuvant trastuzumab in breast cancer
    Paik, Soonmyung
    Kim, Chungyeul
    Wolmark, Norman
    NEW ENGLAND JOURNAL OF MEDICINE, 2008, 358 (13): : 1409 - 1411
12345